secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonnet BioTherapeutics Holdings, Inc. (—)
CIK:        0001106838
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019314
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonnet Q2 cash $3.8M; runway into July/August 2024; pipeline shifts to DPN
--------------------------------------------------------------------------

- Cash $3.8M as of Mar 31, 2024; no debt; expects runway into July 2024, potentially August with cost cuts.
- Q2 R&D expenses $2.2M (down from $3.8M), G&A $1.7M (down from $1.9M) from cost-saving initiatives.
- Received $4.3M net proceeds from NJ NOL sale; entered equity facility with Chardan for capital raise.
- SON-1010 Phase 1 data published showing safety up to 300 ng/kg; SON-080 cleared by DSMB.
- CIPN program placed on hold; targeting diabetic peripheral neuropathy; seeking partnerships for SON-080.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer